Cargando…
Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice
SIMPLE SUMMARY: Grade 3 neuroendocrine neoplasms (NEN G3) are a rare and heterogeneous subtype of NEN and include poorly differentiated neuroendocrine carcinomas and well-differentiated neuroendocrine tumors G3 (NET G3). Standard chemotherapy with platinum plus etoposide may not be appropriate for a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179270/ https://www.ncbi.nlm.nih.gov/pubmed/35681701 http://dx.doi.org/10.3390/cancers14112718 |
_version_ | 1784723233105248256 |
---|---|
author | Luecke, Simone Fottner, Christian Lahner, Harald Jann, Henning Zolnowski, Dominik Quietzsch, Detlef Grabowski, Patricia Cremer, Birgit Maasberg, Sebastian Pape, Ulrich-Frank Mueller, Hans-Helge Gress, Thomas Matthias Rinke, Anja |
author_facet | Luecke, Simone Fottner, Christian Lahner, Harald Jann, Henning Zolnowski, Dominik Quietzsch, Detlef Grabowski, Patricia Cremer, Birgit Maasberg, Sebastian Pape, Ulrich-Frank Mueller, Hans-Helge Gress, Thomas Matthias Rinke, Anja |
author_sort | Luecke, Simone |
collection | PubMed |
description | SIMPLE SUMMARY: Grade 3 neuroendocrine neoplasms (NEN G3) are a rare and heterogeneous subtype of NEN and include poorly differentiated neuroendocrine carcinomas and well-differentiated neuroendocrine tumors G3 (NET G3). Standard chemotherapy with platinum plus etoposide may not be appropriate for all subgroups, but more tailored approaches suffer from the lack of data. In our study, we provide real-world data from a large center-based cohort of the German NET Registry and hope to stimulate efforts to conduct clinical trials for well-defined entities. ABSTRACT: Background: Neuroendocrine neoplasia grade 3 (NEN G3) represents a rare and heterogeneous cancer type with a poor prognosis. The aim of our study was to analyze real-world data from the German NET Registry with a focus on therapeutic and prognostic aspects. Methods: NEN G3 patients were identified within the German NET Registry. Demographic data and data on treatments and outcomes were retrieved. Univariate analyses were performed using the Kaplan–Meier-method. Multivariate analysis was performed using a Cox proportional hazard model. Results: Of 445 included patients, 318 (71.5%) were diagnosed at stage IV. Well-differentiated morphology (NET G3) was described in 31.7%, 60% of cases were classified as neuroendocrine carcinoma (NEC), and the median Ki67 value was 50%. First-line treatment comprised chemotherapy in 43.8%, with differences in the choice of regimen with regard to NET or NEC, and surgery in 41.6% of patients. Median overall survival for the entire cohort was 31 months. Stage, performance status and Ki67 were significant prognostic factors in multivariate analysis. Conclusions: The survival data of our national registry compare favorably to population-based data, probably mainly because of a relatively low median Ki67 of 50%. Nevertheless, the best first- and second-line approaches for specific subgroups remain unclear, and an international effort to fill these gaps is needed. |
format | Online Article Text |
id | pubmed-9179270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91792702022-06-10 Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice Luecke, Simone Fottner, Christian Lahner, Harald Jann, Henning Zolnowski, Dominik Quietzsch, Detlef Grabowski, Patricia Cremer, Birgit Maasberg, Sebastian Pape, Ulrich-Frank Mueller, Hans-Helge Gress, Thomas Matthias Rinke, Anja Cancers (Basel) Article SIMPLE SUMMARY: Grade 3 neuroendocrine neoplasms (NEN G3) are a rare and heterogeneous subtype of NEN and include poorly differentiated neuroendocrine carcinomas and well-differentiated neuroendocrine tumors G3 (NET G3). Standard chemotherapy with platinum plus etoposide may not be appropriate for all subgroups, but more tailored approaches suffer from the lack of data. In our study, we provide real-world data from a large center-based cohort of the German NET Registry and hope to stimulate efforts to conduct clinical trials for well-defined entities. ABSTRACT: Background: Neuroendocrine neoplasia grade 3 (NEN G3) represents a rare and heterogeneous cancer type with a poor prognosis. The aim of our study was to analyze real-world data from the German NET Registry with a focus on therapeutic and prognostic aspects. Methods: NEN G3 patients were identified within the German NET Registry. Demographic data and data on treatments and outcomes were retrieved. Univariate analyses were performed using the Kaplan–Meier-method. Multivariate analysis was performed using a Cox proportional hazard model. Results: Of 445 included patients, 318 (71.5%) were diagnosed at stage IV. Well-differentiated morphology (NET G3) was described in 31.7%, 60% of cases were classified as neuroendocrine carcinoma (NEC), and the median Ki67 value was 50%. First-line treatment comprised chemotherapy in 43.8%, with differences in the choice of regimen with regard to NET or NEC, and surgery in 41.6% of patients. Median overall survival for the entire cohort was 31 months. Stage, performance status and Ki67 were significant prognostic factors in multivariate analysis. Conclusions: The survival data of our national registry compare favorably to population-based data, probably mainly because of a relatively low median Ki67 of 50%. Nevertheless, the best first- and second-line approaches for specific subgroups remain unclear, and an international effort to fill these gaps is needed. MDPI 2022-05-31 /pmc/articles/PMC9179270/ /pubmed/35681701 http://dx.doi.org/10.3390/cancers14112718 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Luecke, Simone Fottner, Christian Lahner, Harald Jann, Henning Zolnowski, Dominik Quietzsch, Detlef Grabowski, Patricia Cremer, Birgit Maasberg, Sebastian Pape, Ulrich-Frank Mueller, Hans-Helge Gress, Thomas Matthias Rinke, Anja Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice |
title | Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice |
title_full | Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice |
title_fullStr | Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice |
title_full_unstemmed | Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice |
title_short | Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice |
title_sort | treatment approaches and outcome of patients with neuroendocrine neoplasia grade 3 in german real-world clinical practice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179270/ https://www.ncbi.nlm.nih.gov/pubmed/35681701 http://dx.doi.org/10.3390/cancers14112718 |
work_keys_str_mv | AT lueckesimone treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT fottnerchristian treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT lahnerharald treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT jannhenning treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT zolnowskidominik treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT quietzschdetlef treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT grabowskipatricia treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT cremerbirgit treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT maasbergsebastian treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT papeulrichfrank treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT muellerhanshelge treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT gressthomasmatthias treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT rinkeanja treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice AT treatmentapproachesandoutcomeofpatientswithneuroendocrineneoplasiagrade3ingermanrealworldclinicalpractice |